Vascular Biogenics (STU:0VB) Beneish M-Score: -3.01 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vascular Biogenics Beneish M-Score?

Vascular Biogenics STU:0VB 10 Beneish M-Score is -3.01 as of Jul. 23, 2026. GuruFocus rates STU:0VB with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Vascular Biogenics's Beneish M-Score or its related term are showing as below:

STU:0VB' s Beneish M-Score Range Over the Past 10 Years
Min: -7.86   Med: -3.4   Max: 7.9
Current: -3.01

During the past 11 years, the highest Beneish M-Score of Vascular Biogenics was 7.90. The lowest was -7.86. And the median was -3.40.


Vascular Biogenics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Vascular Biogenics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vascular Biogenics Beneish M-Score Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.99 7.90 -2.55 -2.47 -3.89

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.40 -3.68 -3.89 -3.29 -3.01

STU:0VB vs MBIO, GNPX, LEXX: Beneish M-Score Comparison

For the Biotechnology subindustry, Vascular Biogenics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Beneish M-Score falls into.



Vascular Biogenics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Vascular Biogenics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 0.5412+0.404 * 0.2046+0.892 * 0.9605+0.115 * 0.1284
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.122+4.679 * 0.05684-0.327 * 0.9559
=-2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was €0.00 Mil.
Revenue was 0 + 0 + 0 + 0.486 = €0.49 Mil.
Gross Profit was 0 + -0.002 + 0.045 + 0.422 = €0.47 Mil.
Total Current Assets was €22.66 Mil.
Total Assets was €22.75 Mil.
Property, Plant and Equipment(Net PPE) was €0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.36 Mil.
Selling, General, & Admin. Expense(SGA) was €10.35 Mil.
Total Current Liabilities was €4.89 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Net Income was -0.807 + -2.465 + -3.089 + -9.262 = €-15.62 Mil.
Non Operating Income was -0.495 + 0.57 + 0 + 0 = €0.08 Mil.
Cash Flow from Operations was -2.18 + -1.577 + -6.345 + -6.889 = €-16.99 Mil.
Total Receivables was €0.00 Mil.
Revenue was 0.061 + 0.103 + 0.173 + 0.169 = €0.51 Mil.
Gross Profit was 0.028 + 0.053 + 0.089 + 0.092 = €0.26 Mil.
Total Current Assets was €33.76 Mil.
Total Assets was €42.87 Mil.
Property, Plant and Equipment(Net PPE) was €8.28 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.22 Mil.
Selling, General, & Admin. Expense(SGA) was €9.61 Mil.
Total Current Liabilities was €8.33 Mil.
Long-Term Debt & Capital Lease Obligation was €1.31 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.486) / (0 / 0.506)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.262 / 0.506) / (0.465 / 0.486)
=0.517787 / 0.95679
=0.5412

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (22.658 + 0) / 22.748) / (1 - (33.761 + 8.282) / 42.872)
=0.003956 / 0.019337
=0.2046

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.486 / 0.506
=0.9605

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.22 / (1.22 + 8.282)) / (0.361 / (0.361 + 0))
=0.128394 / 1
=0.1284

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.352 / 0.486) / (9.606 / 0.506)
=21.300412 / 18.98419
=1.122

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 4.893) / 22.748) / ((1.314 + 8.333) / 42.872)
=0.215096 / 0.225019
=0.9559

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.623 - 0.075 - -16.991) / 22.748
=0.05684

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Vascular Biogenics has a M-score of -2.92 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.01 mean?
Vascular Biogenics (STU:0VB) has a Beneish M-Score of -3.01 as of Jul. 23, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vascular Biogenics and its competitors.
Is Vascular Biogenics' Beneish M-Score too high?
Vascular Biogenics' current Beneish M-Score is -3.01. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' Beneish M-Score compare to MBIO and GNPX?
Vascular Biogenics' Beneish M-Score of -3.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Vascular Biogenics and its competitors. Vascular Biogenics's current Beneish M-Score is -3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current Beneish M-Score of -3.01. The current Beneish M-Score is -3.01. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current Beneish M-Score is -3.01 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vascular Biogenics Business Description

Address 8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.